Wickham Laboratories Ltd is a trusted name in the pharmaceutical and medical device industries with over 50 years of experience in contract testing, research and consultancy.
Wickham Laboratories Ltd is a trusted name in the pharmaceutical and medical device industries with over 50 years of experience in contract testing, research and consultancy. We maintain only the highest standard of quality at all stages while providing rapid turnaround for both routine testing and bespoke one-off projects.
Whether assisting a start-up company demonstrating proof of concept, or working with a global medical device manufacturer, our expert technicians recognise the importance of delivering an exceptional service by taking the time with every client to fully understand their individual requirements.
We are routinely inspected by the MHRA and FDA, operating in accordance with GMP / GLP as well as to ISO and ICH guidelines.
Our services include:
Company name: Wickham Laboratories Ltd
Phone: +44 (0)1329 226600
E-mail: mail@wickhamlabs.co.uk
Website:www.wickhamlabs.co.uk
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.